Rani Therapeutics (NASDAQ:RANI – Get Free Report) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rani Therapeutics to announce earnings of ($0.05) per share and revenue of $1.28 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Rani Therapeutics (NASDAQ:RANI – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.71 million for the quarter, compared to the consensus estimate of $0.93 million. On average, analysts expect Rani Therapeutics to post ($0.17) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.
Rani Therapeutics Stock Up 1.0%
Shares of RANI stock opened at $0.62 on Thursday. Rani Therapeutics has a 12-month low of $0.57 and a 12-month high of $2.63. The firm has a market capitalization of $85.77 million, a price-to-earnings ratio of -2.28 and a beta of 0.69. The firm has a fifty day moving average of $0.78 and a 200-day moving average of $0.95.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on Rani Therapeutics
About Rani Therapeutics
Rani Therapeutics Holdings, Inc is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion.
The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.
See Also
- Five stocks we like better than Rani Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
